CA-ALTIUM-LLC
17.3.2021 09:32:08 CET | Business Wire | Press release
Altium LLC is committed to bringing transformation to the electronics industry through a digital platform that connects design to the supply chain and the manufacturing floor. To achieve this goal, Altium selected Amazon Web Services (AWS) to host Altium 365 , the cloud platform for collaborative PCB design and realization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005247/en/
The Altium 365 cloud-based platform and Altium Designer elevates PCB design by creating seamless collaboration points across the development process, making it the most connected design experience in the industry. This streamlines the product development process and allows engineers and designers to create smart and connected electronic products faster than ever before.
With Altium 365, users can bring together the stakeholders and participants in the electronic design process—even if they do not have Altium Designer—while keeping IPs secure and designs under control. Altium 365 provides a completely new way to share, visualize, and mark-up PCB designs for all stakeholders involved, from design managers to manufacturers, while allowing other designers to connect to the same PCB design with Altium Designer to author changes.
“AWS is central to Altium 365’s success to keep the platform, customers’ designs, and data secure, available and accessible,” said Greg Bellasis, Altium’s Director of Cybersecurity. “A broad portfolio of AWS services and the collaboration with their enterprise support team helps us achieve this goal to ensure ongoing stability, security, and reliability for our users to connect with anyone, from anywhere, in any time zone and from any web-enabled device to get their job done.”
Teams can organize designs, libraries, and participants in one place, and share links to their designs for easy, real-time collaboration. Designs are accessible at any time, on any device, anywhere, thanks to AWS’s proven global infrastructure. By leveraging CAD-specific intelligence, design data can be stored in a way that makes projects, files and version history accessible and easy to navigate on the web.
As Michael Weston, Lead Engineer in Kinetic Vision ’s Product Design and Development Group, explains, “We switched over to Altium 365 in January 2020 because we needed a more stable platform for our data and collaboration methods compared to the local methods we were using, but with the COVID-19 situation, the platform became even more essential because our team members could continue to work remotely. Altium 365 has given us more power to create brilliant work—no matter where our team is working from.”
“There’s a broad recognition that cloud is a more secure place to do collaborative projects than traditional on-premises infrastructures,” said David Pellerin, head of Worldwide Business Development for Infotech/Semiconductor at AWS. “By using the cloud to secure their most sensitive data and improve efficiencies and maximize collaboration, Altium and their customers can free up developers and engineers to focus on innovation.”
By combining the flexibility of sharing and collaboration in the cloud with the power of desktop PCB design software, Altium is making a big leap towards modernizing and transforming the way the electronics industry meets the growing demand for smart and connected products.
ABOUT ALTIUM
Altium LLC , a global software company headquartered in San Diego, California, is accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005247/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
